Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878277 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Coffee Therapy for Improvement of Renal Oxygenation
A Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03878277: Completed Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus, sponsored by University of Colorado, Denver.
NCT03878277 is a Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus that has completed, run by University of Colorado, Denver. The registered enrollment target is 10 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03878277, a Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Over 1.25 million Americans have Type 1 Diabetes (T1D), increasing risk for early death from cardiovascular disease (CVD). Despite advances in glycemic and blood pressure control, a child diagnosed with T1D is expected to live up to 17 years less than non-diabetic peers. The strongest risk factor for CVD and mortality in T1D is diabetic kidney disease (DKD). Current treatments, such as control of hyperglycemia and hypertension, are beneficial, but only partially protect against DKD. This limited progress may relate to a narrow focus on clinical manifestations of disease, rather than on the initial metabolic derangements underlying the initiation of DKD. Renal hypoxia, stemming from a potential metabolic mismatch between increased renal energy expenditure and impaired substrate utilization, is increasingly proposed as a unifying early pathway in the development of DKD. T1D is impacted by several mechanisms which increase renal adenosine triphosphate (ATP) consumption and decrease ATP generation. Caffeine, a methylxanthine, is known to alter kidney function by several mechanisms including natriuresis, hemodynamics and renin-angiotensin-aldosterone system. In contrast, to other natriuretic agents, caffeine is thought to fully inhibit the local tubuloglomerular feedback (TGF) response to increased distal sodium delivery. This observation has broad-ranging implications as caffeine can reduce renal oxygen (O2) consumption without impairing effective renal plasma flow (ERPF) and glomerular filtration rate (GFR). There are also data suggesting that chemicals in coffee besides caffeine may provide important cardio-renal protection. Yet, there are no data examining the impact of coffee-induced natriuresis on intrarenal hemodynamic function and renal energetics in youth-onset T1D. Our overarching hypothesis in the proposed pilot and feasibility trial is that coffee drinking improves renal oxygenation by reducing renal O2 consumption without impairing GFR and ERPF. To address
Primary Outcome
Measured by blood oxygen level dependent (BOLD MRI), before and after Lasix injection;Regions of interest (ROI) analysis for BOLD MRI will be performed on a Leonardo Workstation (Siemens Medical Systems, Germany). Typically, 1 to 3 regions in each, cortex and medulla, per kidney per slice will be defined leading to a total of about 10 ROIs per region (cortex and medulla) per subject. The mean and standard deviation of these 10 measurements will be used a R2\* measurement for the region, for the
Conditions Studied
Interventions
- DRUG Starbucks® Cold brew - 325ml bottle
Study Locations (1)
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 2 |
What the finished NCT03878277 record still lists
NCT03878277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (99% lower).
The record links to 7 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Starbucks® Cold brew - 325ml bottle is the first listed.
NCT03878277 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03878277 about?
NCT03878277 is a clinical study titled "Evaluation of Coffee Therapy for Improvement of Renal Oxygenation". Over 1.25 million Americans have Type 1 Diabetes (T1D), increasing risk for early death from cardiovascular disease (CVD). Despite advances in glycemic and blood pressure control, a child diagnosed with T1D is expected to live up to 17 years less than non-diabetic peers. The strongest risk factor fo...
What is the current status of trial NCT03878277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-07-01. Estimated completion is 2021-09-30.
What conditions does trial NCT03878277 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Complications.
What interventions are being tested in trial NCT03878277?
The interventions under investigation include: Starbucks® Cold brew - 325ml bottle (DRUG).
Who is sponsoring clinical trial NCT03878277?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03878277 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03878277's enrollment target sits among peer trials
10 182nd of 198 higher than 9 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Precision Administration of Anti-thymocyte Globulin With or Without Verapamil
RECRUITING · Phase 2
-
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
RECRUITING · Phase 2
-
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
RECRUITING · Phase 2
-
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
RECRUITING · Phase 2
-
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
RECRUITING · Phase 2
-
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI